Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer

American Journal of Pathology

Volumn 180, Issue 3, 2012, Pages 895-903

  Sircar, Kanishka ^a   Huang, Heng ^c   Hu, Limei ^a   Cogdell, David ^a   Dhillon, Jasreman ^a   Tzelepi, Vassiliki ^b   Efstathiou, Eleni ^b   Koumakpayi, Ismal H ^d   Saad, Fred ^d   Luo, Dijun ^c   Bismar, Tarek A ^e   Aparicio, Ana ^b   Troncoso, Patricia ^a   Navone, Nora ^b   Zhang, Wei ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c The University of Texas at Arlington   (United States)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ASPARTATE AMMONIA LIGASE; DNA; MESSENGER RNA; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE EXPRESSION PROFILING; GENE SILENCING; GENETIC ASSOCIATION; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; THERAPY RESISTANCE; TRANSCRIPTOMICS; TUMOR XENOGRAFT;

ANIMALS; ASPARTATE-AMMONIA LIGASE; DNA; DNA COPY NUMBER VARIATIONS; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; GENOME-WIDE ASSOCIATION STUDY; MALE; MICE; MICE, INBRED C57BL; MICE, SCID; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 84863171450     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.11.030     Document Type: Article

References (38)

1. A. Jemal, R. Siegel, J. Xu, E. Ward Cancer statistics CA Cancer J Clin 60 2010 277 300
2. D.P. Petrylak, C.M. Tangen, M.H. Hussain, P.N. Lara Jr, J.A. Jones, M.E. Taplin, P.A. Burch, D. Berry, C. Moinpour, M. Kohli, M.C. Benson, E.J. Small, D. Raghavan, E.D. Crawford Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
3. I.F. Tannock, R. de Wit, W.R. Berry, J. Horti, A. Pluzanska, K.N. Chi, S. Oudard, C. Theodore, N.D. James, I. Turesson, M.A. Rosenthal, M.A. Eisenberger Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
4. A.H. Reid, G. Attard, E. Barrie, J.S. de Bono CYP17 inhibition as a hormonal strategy for prostate cancer Nat Clin Pract Urol 5 2008 610 620
5. C. Tran, S. Ouk, N.J. Clegg, Y. Chen, P.A. Watson, V. Arora, J. Wongvipat, P.M. Smith-Jones, D. Yoo, A. Kwon, T. Wasielewska, D. Welsbie, C. Chen, C.S. Higano, T.M. Beer, D.T. Hung, H.I. Scher, M. Jung, C.L. Sawyers Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 2009 787 790
6. K. Sircar, M. Yoshimoto, F.A. Monzon, I.H. Koumakpayi, R.L. Katz, A. Khanna, K. Alvarez, G. Chen, A.D. Darnel, A.G. Aprikian, F. Saad, T.A. Bismar, J.A. Squire PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer J Pathol 218 2009 505 513
7. D.J. Mulholland, L.M. Tran, Y. Li, H. Cai, A. Morim, S. Wang, S. Plaisier, I.P. Garraway, J. Huang, T.G. Graeber, H. Wu Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth Cancer Cell 19 2011 792 804
8. Q. Liu, D. Jernigan, Y. Zhang, A. Fatatis Implication of platelet-derived growth factor receptor alpha in prostate cancer skeletal metastasis Chin J Cancer 30 2011 612 619
9. U.R. Chandran, C. Ma, R. Dhir, M. Bisceglia, M. Lyons-Weiler, W. Liang, G. Michalopoulos, M. Becich, F.A. Monzon Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process BMC Cancer 7 2007 64
10. S. Varambally, J. Yu, B. Laxman, D.R. Rhodes, R. Mehra, S.A. Tomlins, R.B. Shah, U. Chandran, F.A. Monzon, M.J. Becich, J.T. Wei, K.J. Pienta, D. Ghosh, M.A. Rubin, A.M. Chinnaiyan Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression Cancer Cell 8 2005 393 406
11. A. Ylip, K.K. Hunt, J. Yang, A.J. Lazar, K.E. Torres, D.C. Lev, M. Nykter, R.E. Pollock, J. Trent, W. Zhang Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors Cancer 117 2011 380 389
12. J. Yang, D. Cogdell, D. Yang, L. Hu, H. Li, H. Zheng, X. Du, Y. Pang, J. Trent, K. Chen, W. Zhang Deletion of the WWOX gene and frequent loss of its protein expression in human osteosarcoma Cancer Lett 291 2010 31 38
13. N.D. Price, J. Trent, A.K. El-Naggar, D. Cogdell, E. Taylor, K.K. Hunt, R.E. Pollock, L. Hood, I. Shmulevich, W. Zhang Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas Proc Natl Acad Sci U S A 104 2007 3414 3419
14. N. Nguyen, H. Huang, S. Oraintara, A. Vo Stationary wavelet packet transform and dependent laplacian bivariate shrinkage estimator for array-CGH data smoothing J Comput Biol 17 2010 139 152
15. S. Iadevaia, Y. Lu, F.C. Morales, G.B. Mills, P.T. Ram Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis Cancer Res 70 2010 6704 6714
16. E. Efstathiou, P. Troncoso, S. Wen, K.A. Do, C.A. Pettaway, L.L. Pisters, T.J. McDonnell, C.J. Logothetis Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer Clin Cancer Res 13 2007 1224 1231
17. G.N. Thalmann, P.E. Anezinis, S.M. Chang, H.E. Zhau, E.E. Kim, V.L. Hopwood, S. Pathak, A.C. von Eschenbach, L.W. Chung Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer Cancer Res 54 1994 2577 2581
18. Z.G. Li, P. Mathew, J. Yang, M.W. Starbuck, A.J. Zurita, J. Liu, C. Sikes, A.S. Multani, E. Efstathiou, A. Lopez, J. Wang, T.V. Fanning, V.G. Prieto, V. Kundra, E.S. Vazquez, P. Troncoso, A.K. Raymond, C.J. Logothetis, S.H. Lin, S. Maity, N.M. Navone Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms J Clin Invest 118 2008 2697 2710
19. J.R. Jabbur, W. Zhang p53 Antiproliferative function is enhanced by aspartate substitution at threonine 18 and serine 20 Cancer Biol Ther 1 2002 277 283
20. H. Cui, S. Darmanin, M. Natsuisaka, T. Kondo, M. Asaka, M. Shindoh, F. Higashino, J. Hamuro, F. Okada, M. Kobayashi, K. Nakagawa, H. Koide Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin Cancer Res 67 2007 3345 3355
21. P.L. Lorenzi, W.C. Reinhold, M. Rudelius, M. Gunsior, U. Shankavaram, K.J. Bussey, U. Scherf, G.S. Eichler, S.E. Martin, K. Chin, J.W. Gray, E.C. Kohn, I.D. Horak, D.D. Von Hoff, M. Raffeld, P.K. Goldsmith, N.J. Caplen, J.N. Weinstein Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells Mol Cancer Ther 5 2006 2613 2623
22. B.D. Parsons, A. Schindler, D.H. Evans, E. Foley A direct phenotypic comparison of siRNA pools and multiple individual duplexes in a functional assay PLoS One 4 2009 e8471
23. R. Kittler, V. Surendranath, A.K. Heninger, M. Slabicki, M. Theis, G. Putz, K. Franke, A. Caldarelli, H. Grabner, K. Kozak, J. Wagner, E. Rees, B. Korn, C. Frenzel, C. Sachse, B. Sonnichsen, J. Guo, J. Schelter, J. Burchard, P.S. Linsley, A.L. Jackson, B. Habermann, F. Buchholz Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies Nat Methods 4 2007 337 344
24. M.A. Barranco, A. Alcaraz, J.M. Corral, M. Sole, C. Mallofre, J. Llopis, A. Rodriguez, M.J. Ribal, R. Alvarez-Vijande, P. Carretero Numeric alterations in chromosomes 7 and 8 detected by fluorescent in situ hybridization correlate with high-grade localized prostate cancer Eur Urol 34 1998 419 425
25. M. Skacel, A.H. Ormsby, J.D. Pettay, E.K. Tsiftsakis, L.S. Liou, E.A. Klein, H.S. Levin, C.D. Zippe, R.R. Tubbs Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray Hum Pathol 32 2001 1392 1397
26. A. Alcaraz, S. Takahashi, J.A. Brown, J.F. Herath, E.J. Bergstralh, J.J. Larson-Keller, M.M. Lieber, R.B. Jenkins Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer Cancer Res 54 1994 3998 4002
27. M.G. Bandyk, L. Zhao, P. Troncoso, L.L. Pisters, J.L. Palmer, A.C. von Eschenbach, L.W. Chung, J.C. Liang Trisomy 7: a potential cytogenetic marker of human prostate cancer progression Genes Chromosomes Cancer 9 1994 19 27
28. T. Visakorpi, A.H. Kallioniemi, A.C. Syvanen, E.R. Hyytinen, R. Karhu, T. Tammela, J.J. Isola, O.P. Kallioniemi Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization Cancer Res 55 1995 342 347
29. J.H. Kim, S.M. Dhanasekaran, R. Mehra, S.A. Tomlins, W. Gu, J. Yu, C. Kumar-Sinha, X. Cao, A. Dash, L. Wang, D. Ghosh, K. Shedden, J.E. Montie, M.A. Rubin, K.J. Pienta, R.B. Shah, A.M. Chinnaiyan Integrative analysis of genomic aberrations associated with prostate cancer progression Cancer Res 67 2007 8229 8239
30. B.S. Taylor, N. Schultz, H. Hieronymus, A. Gopalan, Y. Xiao, B.S. Carver, V.K. Arora, P. Kaushik, E. Cerami, B. Reva, Y. Antipin, N. Mitsiades, T. Landers, I. Dolgalev, J.E. Major, M. Wilson, N.D. Socci, A.E. Lash, A. Heguy, J.A. Eastham, H.I. Scher, V.E. Reuter, P.T. Scardino, C. Sander, C.L. Sawyers, W.L. Gerald Integrative genomic profiling of human prostate cancer Cancer Cell 18 2010 11 22
31. I.N. Holcomb, J.M. Young, I.M. Coleman, K. Salari, D.I. Grove, L. Hsu, L.D. True, M.P. Roudier, C.M. Morrissey, C.S. Higano, P.S. Nelson, R.L. Vessella, B.J. Trask Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer Cancer Res 69 2009 7793 7802
32. N.G. Richards, S.M. Schuster Mechanistic issues in asparagine synthetase catalysis Adv Enzymol Relat Areas Mol Biol 72 1998 145 198
33. M.J. Scian, K.E. Stagliano, D. Deb, M.A. Ellis, E.H. Carchman, A. Das, K. Valerie, S.P. Deb, S. Deb Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes Oncogene 23 2004 4430 4443
34. I. Osman, M. Drobnjak, M. Fazzari, J. Ferrara, H.I. Scher, C. Cordon-Cardo Inactivation of the p53 pathway in prostate cancer: impact on tumor progression Clin Cancer Res 5 1999 2082 2088
35. J.H. Hughes, M.B. Cohen, R.A. Robinson p53 Immunoreactivity in primary and metastatic prostatic adenocarcinoma Mod Pathol 8 1995 462 466
36. N.G. Richards, M.S. Kilberg Asparagine synthetase chemotherapy Annu Rev Biochem 75 2006 629 654
37. P.L. Lorenzi, J.N. Weinstein, N.J. Caplen Materials and Methods Directed to Asparagine Synthetase and Asparaginase Therapies U.S. Patent US20090311233 Dec. 17, 2009
38. R.H. Kim, J.M. Coates, T.L. Bowles, G.P. McNerney, J. Sutcliffe, J.U. Jung, R. Gandour-Edwards, F.Y. Chuang, R.J. Bold, H.J. Kung Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis Cancer Res 69 2009 700 708